Benutzer: Gast  Login
Titel:

Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer -- A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System

Autor(en):
Lux, Michael P.; Wöckel, Achim; Benedict, Agnes; Buchholz, Stefan; Kreif, No'emi; Harbeck, Nadia; Kreienberg, Rolf; Kaufmann, Manfred; Beckmann, Matthias W.; Jonat, Walter; Hadji, Peyman; Distler, Wolfgang; Raab, Guenther; Tesch, Hans; Weyers, Georg; Possinger, Kurt; Schneeweiss, Andreas
Abstract:
Background: In the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial, the aromatase inhibitor (AI) anastrozole had a significantly better efficacy and safety profile than tamoxifen as initial adjuvant therapy for hormone receptor-positive (HR+) early breast cancer (EBC) in postmenopausal patients. To compare the combined long-term clinical and economic benefits, we carried out a cost-effectiveness analysis (CEA) of anastrozole versus tamoxifen based on the data of the 100month analysis of...     »
Stichworte:
Tamoxifen; QALY; Anastrozole; Cost-effectiveness analysis; Cost-utility analysis; Incremental cost-effectiveness ratio
Zeitschriftentitel:
Onkologie
Jahr:
2010
Band / Volume:
33
Heft / Issue:
4
Seitenangaben Beitrag:
155--166
Volltext / DOI:
doi:10.1159/000286233
Verlag / Institution:
S. Karger GmbH
Verlagsort:
Freiburg, Germany
Print-ISSN:
1423-0240
E-ISSN:
2296-5262
Hinweise:
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
 BibTeX